Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F3KC
|
|||
| Former ID |
DNCL002388
|
|||
| Drug Name |
Indium-111
|
|||
| Synonyms |
ABT-806
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2/3 | [1] | |
| Company |
Abbott Laboratories Abbott
|
|||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00442533) Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.